Aardvark Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
Aardvark Therapeutics reported Q2 2026 results with critical setbacks: FDA placed a full clinical hold on ARD-101 (its lead program for Prader-Willi Syndrome hyperphagia) in May 2026 following a voluntary pause; the company terminated both Phase 3 HERO and OLE trials in June 2026 and does not intend to resume them as designed. Cash and equivalents stand at $73.9M (down from $91.2M at Q1 2026), funding operations into late 2027. Q2 net loss was $14.4M; R&D spend declined to $10.5M from $13.1M YoY due to trial pause, but G&A rose to $4.6M from $2.7M due to headcount and severance from a June workforce reduction.
Why this rating
Clinical hold on sole lead asset and terminated trials are existential threats. $73.9M cash runway is ~45% of market cap; company must demonstrate path forward or face dilution/restructuring. Major trajectory risk.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.